Caroline Seymour

China’s Center for Drug Evaluation Grants Breakthrough Therapy Designation to Ivonescimab in TNBC

FDA Grants Breakthrough Therapy Designation to Zenocutuzumab in NRG1+ Cholangiocarcinoma

Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC

Phase 2 BNT111/Cemiplimab Data Prove Positive in PD-(L)1-Relapsed/Refractory Melanoma

Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced Urothelial Carcinoma

Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology

FDA Grants Orphan Drug Designation to Cintredekin Besudotox in Glioblastoma

How AI-Driven Platforms Can Transform Clinical Trial Efficiency in Cancer Care

From Overload to Insight: Why AI Is Becoming an Essential Partner in Oncology

Simplifying Care Navigation in Oncology: A Painless Path to Better Support